摘要
目的:观察帕立骨化醇治疗血液透析患者继发性甲状旁腺功能亢进症(SHPT)的有效性及安全性。方法:选择2016年8月至2016年12月深圳市第二人民医院血液透析中心维持性血液透析伴发SHPT患者12例,全段甲状旁腺素(iPTH)600~1500pg·m L^(-1),初始给予帕立骨化醇5μg·次^(-1),每周3次治疗,根据血清iPTH及钙磷水平调整剂量。结果:本研究12例患者应用帕立骨化醇治疗3个月后,按照美国肾脏病与透析病人生存质量指导指南透析患者血清iPTH目标范围150~300pg·mL^(-1),达标率为25.0%,降幅最高达到79.3%,最低降幅也有26.0%。结论:帕立骨化醇注射液能有效降低血清iPTH水平,治疗SHPT,治疗过程中注意监测血钙血磷水平。
Objective To observe the efficacy and safety of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. Methods 12 patients with secondary hyper-parathyroidism, whose whole parathyroid hormone（iPTH） were 600 - 1500pg/ml, were selected from the hemodialysis center of Shenzhen second people＇s hospital from August 2016 to November 2016. These patients were initially treated with paricalcitol 5μg/time, three times a week,and were adjusted the dosage according to serum iPTH and calcium phosphorus level. Results Following the K/DOQI guide,the target range of dialysis patients was 150 - 300pg/ml.In this group, 12 cases were treated with paricalcitol for 3 months,the target rate of serum iPTH was 25%, and the decline ranged from 26% to 79.3%. Conclusion Paricalcitol injection can effectively reduce serum iPTH levels, treat SHPT, and monitor blood calcium phosphorus levels during treatment.
作者
刘洪萍
廖莹
李彤
许慧丽
郭健英
LIU Hongoping;LIAO Ying;LI Tong;XU Hui-li;GUO Jian-ying(Shenzhen Second People＇S Hospital, Guangdong Shenzhen 518035)
出处
《深圳中西医结合杂志》
2018年第6期14-15,共2页
Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
作者简介
刘洪萍，女，副主任医师，主要研究方向是糖尿病肾病，慢性肾功能不全。
